Trials / Recruiting
RecruitingNCT06575400
A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People
A Phase 1, Randomised, Single-blind, Placebo-controlled Trial to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Subcutaneous Doses of BI 3804379 in Healthy Male and Female Subjects
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 106 (estimated)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PKs) of BI 3804379 in healthy male and female subjects following administration of single rising doses and administration of multiple rising doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 3804379 | BI 3804379 |
| DRUG | Placebo matching BI 3804379 | Placebo matching BI 3804379 |
Timeline
- Start date
- 2024-09-12
- Primary completion
- 2028-02-02
- Completion
- 2028-03-20
- First posted
- 2024-08-28
- Last updated
- 2026-03-31
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06575400. Inclusion in this directory is not an endorsement.